Dashboard Tools Market News Investing Ideas Pricing About Us
Sign Up
Log in
Eagle Pharmaceuticals Inc banner

Eagle Pharmaceuticals Inc
NASDAQ:EGRX

Watchlist Manager
Eagle Pharmaceuticals Inc Logo
Eagle Pharmaceuticals Inc
NASDAQ:EGRX
Watchlist
Price: 0.2 USD -20% Market Closed
Market Cap: $2.6m
Write Note Create Alert Ask AI
Financials Section:
Income Statement Balance Sheet Cash Flow Statement
|
Revenue Breakdown

Cash Flow Statement

Operating Cash Flow
+
3Y
-
5Y
-
10Y
+17%
Investing Cash Flow
+
3Y
-30%
5Y
-450%
10Y
-79 267%
Financing Cash Flow
+
3Y
-
5Y
+149%
10Y
-39%

Cash Flow Statement
Eagle Pharmaceuticals Inc

Rotate your device to view
Cash Flow Statement
Currency: USD
Jun-2013 Sep-2013 Dec-2013 Mar-2014 Jun-2014 Sep-2014 Dec-2014 Mar-2015 Jun-2015 Sep-2015 Dec-2015 Mar-2016 Jun-2016 Sep-2016 Dec-2016 Mar-2017 Jun-2017 Sep-2017 Dec-2017 Mar-2018 Jun-2018 Sep-2018 Dec-2018 Mar-2019 Jun-2019 Sep-2019 Dec-2019 Mar-2020 Jun-2020 Sep-2020 Dec-2020 Mar-2021 Jun-2021 Sep-2021 Dec-2021 Mar-2022 Jun-2022 Sep-2022 Dec-2022 Mar-2023 Jun-2023
Operating Cash Flow
Net Income
(11)
(6)
(7)
(10)
(8)
(18)
(20)
8
2
1
3
(18)
3
25
81
105
97
100
52
32
30
28
32
38
42
26
14
2
(5)
5
12
14
18
6
(9)
36
23
21
36
(3)
12
Depreciation & Amortization
0
0
0
0
0
0
0
0
0
0
0
0
1
1
2
2
3
3
4
4
4
4
4
4
4
4
5
5
5
4
4
3
3
4
4
4
5
7
12
17
21
Change in Deffered Taxes
0
0
0
0
0
0
0
0
0
0
0
0
0
0
(30)
(26)
(22)
(18)
17
13
10
7
(2)
(3)
(4)
(5)
0
0
(1)
(1)
(2)
(1)
1
(2)
(4)
(7)
(9)
(6)
(8)
(8)
(8)
Stock-Based Compensation
0
0
0
1
1
1
1
1
2
3
4
6
7
8
10
11
12
14
15
17
18
18
19
20
20
21
22
24
25
24
25
24
22
21
20
17
18
17
16
17
16
Other Non-Cash Items
2
3
3
3
2
1
1
1
2
3
4
5
6
8
9
12
14
16
16
16
25
25
27
28
21
22
22
31
29
35
35
22
28
22
27
32
31
39
28
27
24
Cash Taxes Paid
0
0
0
0
0
0
0
0
0
1
1
1
0
3
3
0
8
9
11
11
7
4
2
(4)
3
7
7
13
4
3
6
7
10
10
10
10
16
23
28
29
37
Cash Interest Paid
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
1
2
2
2
3
2
2
2
3
3
2
2
1
1
1
1
1
1
2
3
4
Change in Working Capital
(3)
(3)
0
0
(1)
3
(3)
5
2
2
(17)
(20)
(33)
(37)
(9)
(56)
(14)
(29)
(30)
12
(24)
(24)
(8)
7
28
50
14
(5)
3
(16)
1
18
(5)
11
10
(64)
(13)
(41)
(16)
1
(58)
Cash from Operating Activities
(11)
N/A
(6)
+48%
(4)
+31%
(6)
-51%
(7)
-15%
(14)
-97%
(22)
-57%
14
N/A
7
-53%
7
+7%
(10)
N/A
(32)
-234%
(23)
+29%
(3)
+86%
53
N/A
38
-29%
78
+107%
73
-7%
59
-19%
76
+29%
44
-42%
40
-9%
52
+30%
74
+41%
90
+23%
97
+8%
56
-42%
33
-41%
32
-4%
27
-16%
50
+87%
57
+15%
44
-22%
40
-10%
28
-29%
1
-96%
36
+3 044%
21
-40%
51
+139%
34
-33%
(9)
N/A
Investing Cash Flow
Capital Expenditures
(0)
(0)
(0)
(0)
(0)
(0)
(0)
(0)
(0)
(1)
(2)
(3)
(2)
(16)
(16)
(16)
(16)
(3)
(5)
(5)
(4)
(3)
(0)
(0)
(0)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(0)
(0)
(0)
(0)
(0)
(0)
(0)
(0)
Other Items
0
2
0
0
0
(20)
0
(36)
(110)
(24)
0
13
87
21
(30)
(27)
(27)
(27)
0
0
0
0
0
0
0
0
0
(18)
(18)
(18)
(18)
(5)
(5)
(5)
(5)
0
(75)
(87)
(87)
(99)
(24)
Cash from Investing Activities
(0)
N/A
1
N/A
(0)
N/A
(0)
-40%
(0)
+29%
(20)
-40 000%
(0)
+100%
(36)
-72 020%
(110)
-206%
(25)
+77%
(2)
+93%
10
N/A
84
+723%
5
-94%
(46)
N/A
(43)
+7%
(43)
0%
(30)
+30%
(5)
+83%
(5)
+13%
(4)
+4%
(3)
+36%
(0)
+95%
(0)
-123%
(0)
-55%
(1)
-62%
(1)
-7%
(19)
-2 281%
(18)
+1%
(18)
+1%
(18)
0%
(6)
+69%
(6)
+0%
(5)
+4%
(5)
+2%
(0)
+98%
(76)
-68 655%
(87)
-15%
(87)
+0%
(99)
-14%
(24)
+76%
Financing Cash Flow
Net Issuance of Common Stock
10
10
0
56
46
46
46
55
55
55
56
1
0
(15)
(33)
(45)
(55)
(53)
(39)
(34)
(22)
(19)
(64)
(59)
(76)
(65)
(18)
(18)
(7)
(30)
(31)
(30)
(30)
(15)
(19)
(27)
(23)
(24)
(16)
(8)
(10)
Net Issuance of Debt
10
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
50
49
0
48
(5)
(4)
(6)
(6)
(5)
(6)
106
(4)
(4)
(5)
(116)
(7)
(8)
(8)
(8)
(8)
7
13
29
24
Other
0
(0)
(1)
0
0
0
0
0
0
0
0
0
0
(0)
(0)
(1)
(1)
(1)
(1)
(19)
(21)
(20)
(20)
(2)
(0)
(0)
(1)
(2)
(2)
(2)
(2)
(2)
(2)
(2)
(2)
(1)
(1)
(1)
(3)
(3)
(3)
Cash from Financing Activities
19
N/A
10
-49%
9
-5%
56
+505%
46
-18%
46
+0%
47
+1%
55
+18%
55
+1%
55
0%
56
+1%
1
-99%
0
-31%
(15)
N/A
(34)
-127%
(46)
-36%
(55)
-21%
(4)
+92%
8
N/A
(4)
N/A
5
N/A
(44)
N/A
(88)
-101%
(67)
+24%
(82)
-23%
(71)
+14%
(24)
+66%
85
N/A
(13)
N/A
(36)
-173%
(38)
-6%
(148)
-291%
(38)
+74%
(24)
+36%
(28)
-16%
(37)
-29%
(32)
+13%
(19)
+42%
(6)
+67%
18
N/A
12
-33%
Change in Cash
Net Change in Cash
8
N/A
5
-34%
5
-3%
50
+862%
39
-22%
12
-69%
25
+103%
33
+32%
(48)
N/A
37
N/A
44
+19%
(22)
N/A
62
N/A
(13)
N/A
(26)
-107%
(51)
-93%
(20)
+60%
38
N/A
62
+62%
68
+10%
45
-34%
(6)
N/A
(36)
-468%
6
N/A
8
+22%
26
+230%
31
+19%
100
+222%
0
-100%
(28)
N/A
(7)
+76%
(97)
-1 362%
1
N/A
10
+1 873%
(5)
N/A
(36)
-550%
(72)
-102%
(84)
-17%
(42)
+50%
(48)
-12%
(21)
+55%
Free Cash Flow
Free Cash Flow
(11)
N/A
(6)
+47%
(4)
+31%
(6)
-51%
(7)
-14%
(14)
-96%
(22)
-57%
14
N/A
6
-55%
6
-9%
(12)
N/A
(35)
-203%
(25)
+28%
(19)
+26%
37
N/A
22
-41%
62
+183%
69
+12%
54
-23%
72
+34%
40
-44%
37
-7%
52
+40%
73
+40%
90
+23%
97
+7%
55
-43%
32
-42%
31
-4%
26
-16%
49
+89%
56
+15%
44
-22%
39
-10%
28
-29%
1
-96%
35
+3 362%
21
-41%
51
+141%
34
-33%
(9)
N/A

See Also

Summary
EGRX intrinsic value, competitors valuation, and company profile.
DCF Valuation
EGRX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
EGRX stock valuation using valuation multiples.
Wall Street Estimates
EGRX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
EGRX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Follow us
Join more than 319,700+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.